The Nocebo Effect and Chronic Pain: Why Words Matter

A sentence from an appointment can stay with you long after you leave. Pain research gives us reasons to choose those sentences carefully, while keeping the medical facts intact.

Imagine being told that a movement will certainly damage your back, without a clear explanation of how that conclusion was reached. You might leave more frightened of the movement than when you arrived. This hypothetical example illustrates why an explanation deserves scrutiny; it does not establish that any later pain would be a nocebo effect.

In the later part of his 2009 seminar segment, Howard Schubiner discusses how expectations and social context might shape symptoms. His historical account makes claims beyond what that segment demonstrates. Modern nocebo research offers a narrower, testable question: can changing the context or expectation change a person's symptom experience?

What the evidence says about the nocebo effect

A systematic review published in 2024 combined 130 independent studies with 8,219 participants. It found an average nocebo effect of medium size across the outcomes studied, with substantial variation between studies. The researchers required a nocebo condition and a comparison condition, which helps distinguish the effect from symptoms that would have occurred anyway.

This supports the existence of nocebo effects. It does not tell us what proportion of a particular person's chronic pain comes from expectation. It also does not mean that every symptom reported after a placebo is a nocebo effect. Background symptoms, natural fluctuations, and other factors can contribute.

A person's worry is understandable information about what they have experienced. It is not a diagnosis or a character flaw.

A pain experiment shows why context matters

In a 2011 experiment by Bingel and colleagues, healthy volunteers received a fixed concentration of the opioid remifentanil while experiencing heat pain. The researchers changed expectations about the treatment. Positive expectations increased the observed pain relief; negative expectations eliminated the measured analgesic benefit under those experimental conditions. Brain imaging also showed changes associated with the different expectations.

The experiment demonstrates that context can influence pain even when an active drug is being given. It was not a trial showing that positive thinking treats chronic pain or that prescribed medication can be replaced. Brief laboratory heat pain and years of daily symptoms are different clinical situations.

What has been found in people with chronic pain?

A 2024 study of 65 cancer survivors with chronic musculoskeletal pain examined expectations during a randomized trial of a topical patch versus placebo. Over 14 days, higher baseline expectations of side effects were associated with less pain improvement and some adverse-event outcomes.

The distinction in the study design matters: patch treatment was randomized, but expectations were measured rather than randomly assigned. The association therefore does not, by itself, prove that expectations caused the differences. The small sample, short follow-up, and selected patient group also limit generalization.

For everyday care, the finding is a reason to ask about concerns before treatment and take them seriously. It is not permission to attribute a rash, new pain, or another reported problem to anxiety without assessment.

Can other people's experiences shape expectations?

They can, although the circumstances matter. A 2024 systematic review of 20 studies involving 1,388 participants found that observing others could induce nocebo responses in the studied settings. The size of the effect varied with the comparison used.

This is relevant to the seminar's interest in social influence. It does not establish that chronic illnesses are contagious through conversation, that a diagnosis creates a disease, or that patient communities are harmful.

Someone else's recovery or difficult treatment experience may be worth hearing. It still cannot tell you exactly what will happen to you. If a story leaves you worried, bring the specific concern to a clinician: Does this risk apply to my situation, and how would we recognize it?

Explaining nocebo can help, but it has a tradeoff

In two preregistered experiments published in 2024, researchers studied how nocebo education affected community adults responding to fictional treatment scenarios. Education reduced general expectations of side effects and increased perceived control. Participants also expressed greater intentions to avoid side-effect information.

These were vignette experiments, not proof of reduced clinical pain or safer medication use. The information-avoidance finding deserves attention: teaching people about expectations should not leave them afraid to learn about genuine risks.

If the message becomes Don't read about side effects or you will cause them, the explanation has gone wrong. People need understandable information and a clear response plan.

How to discuss risks without creating unnecessary fear

NICE's shared decision-making guidance recommends absolute risks, consistent denominators, and both positive and negative framing. The aim is to help people understand the choice.

Here is a fictional numerical example, not a risk estimate for any treatment: if 6 of 100 people experience an effect over four weeks, 94 of 100 do not. Both statements belong in the conversation, along with what the effect means and what to do if it occurs.

Severity matters as well as frequency. A rare serious complication and a common mild inconvenience require different explanations. Your clinician should connect the information to your circumstances and acknowledge when a precise estimate is unavailable.

You can ask for the discussion in smaller pieces, request written information, or ask the clinician to explain an unfamiliar word. Understanding risk should leave you better prepared to act, including when that action is seeking help.

Examples of more useful pain conversations

The examples below are communication suggestions, not findings from a trial or scripts that establish a diagnosis.

None of these requires certainty that everything is safe. They invite the missing information into the conversation. For help preparing the broader discussion, see our chronic pain management plan.

How Cindra should apply this research

Cindra's proposed role is to help a person understand and use information between appointments. For example, it could help them turn an alarming phrase into a question for the clinician who used it. It should preserve the original medical meaning and uncertainty when summarizing a care plan.

We would want responses to avoid unsupported predictions that an activity will cause damage or that symptoms are certainly harmless. The system should also avoid saying that a person caused pain by worrying. Acknowledging fear does not require endorsing every feared outcome.

A discussion of nocebo should keep relevant treatment risks accessible. If a user reports a possible adverse effect, the response should prioritize appropriate assessment rather than automatically offering reassurance about expectations. The user should be able to skip the explanation and ask for practical help.

These are proposed product requirements, not tested clinical capabilities. Evaluation should examine whether users understand risks, whether important details are lost in summaries, and whether the system delays appropriate care. A calmer conversation would not count as success if it made someone less likely to report a serious symptom.

About the source

This article takes a communication question raised by Howard Schubiner's Mind Body Syndrome seminar, Part 1A, uploaded by yourpainisreal on September 8, 2009, and examines it using later research. We reviewed the full auto-generated captions for this segment and selected visual frames, not the complete audiovisual recording or the rest of the seminar. The nocebo analysis and Cindra applications are our own additions.

Educational commentary and proposed product requirements. Sources checked October 27, 2026. This article has not undergone clinical review and does not provide an individualized care plan. Cindra requires product-specific evaluation before clinical benefit can be claimed.